Abstracts tagged "rheumatic disease and health care cost"

Abstract Number: 205 • ACR/ARP Annual Meeting 2019
Does a Mandatory Non-medical Switch from Originator to Biosimilar Etanercept Lead to Increase in Healthcare Use and Costs? A Danish Register-based Study of 1620 Patients with Inflammatory Arthritis
Bente Glintborg ¹, Rikke Ibsen ², Rebekka Elisabeth Qwist Bilbo ³, Merete Lund Hetland¹ and Jakob Kjellberg ³, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²i2minds, Aarhus, Denmark, ³VIVE, The Danish Centre for Social Science Research, Copenhagen, Denmark
Background/Purpose: Marketing of cheaper biosimilar biological agents has created financial incentives for switching from the corresponding originator drugs (=non-medical switch). The economic benefit might potentially…